Navigation Links
Lupin Launches Additional Strengths of Generic Lotrel® Capsules
Date:7/6/2011

BALTIMORE, July 6, 2011 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration (US FDA) has granted final approval for its Amlodipine / Benazepril 5mg/40mg, and 10mg/40mg capsules.  Commercial shipments of the product have already commenced.  This approval completes the product line as the Company was granted final approval for Amlodipine / Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules in February 2010.  

Lupin's Amlodipine / Benazepril capsules are the AB-rated generic equivalent of Novartis' *Lotrel® capsules indicated for the treatment of hypertension.   Amlodipine / Benazepril 5mg/40mg, and 10mg/40mg capsules had annual sales of approximately $290 million for the twelve months ended March 2011, based on IMS Health sales data.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant market share in Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition holding global leadership positions in the Anti-TB and Cephalosporins space.  

Today, Lupin is the 5th largest and fastest growing Top 5 generics player in the US (by prescriptions), the only Asian company to achieve that distinction.   The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS)

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 million and Rs. 8,626  million respectively.  Please visit http://www.lupinworld.com for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited.  Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release

*Lotrel® is a registered trademark of Novartis Corp.

For More Information:
Contact: Edith St-Hilaire
Director of Marketing
(410) 576-2000


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupin Announces Launch of Generic Levaquin® Tablets
2. HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer
3. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
4. Lupin Expands Branded Play
5. JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
6. Global Medical Imaging Launches Worlds First Ultrasound Maintenance App
7. UCB Launches Research Alliance with Harvard University
8. Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System
9. Hocoma Launches New Version of its Established Gait Training Device LokomatPro
10. American Pain Foundation Launches New Educational Campaign, "Explain Your Pain," to Help Hispanic Americans Better Understand Chronic Pain and Pain Management
11. ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SAN FRANCISCO , January 19, 2017 The global  ... a new report by Grand View Research, Inc. The heightening prevalence of cardiac ... governing the growth of Pacemaker globally. In addition, technological enhancements in these devices ... Reading ... Grand View Research Logo ...
(Date:1/19/2017)... Jan. 18, 2017  ViewRay, Inc. (Nasdaq: ... and only clinical MRI-guided radiation therapy system, announced today ... approximately $26.1 million through a private placement of ... led the financing and was joined by certain ... and Kearny Venture Partners, and an additional new ...
(Date:1/19/2017)... 18, 2017  Magnetic Insight Inc., leader in ... an agreement with inviCRO LLC to develop intuitive ... system based on inviCRO,s VivoQuant™ visualization and post ... a complete MPI solution package with the Momentum ... cell imaging in vivo. MPI is ...
Breaking Medicine Technology:
(Date:1/19/2017)... PA (PRWEB) , ... January 19, 2017 , ... Allegheny ... experience of patients who seek access to the Network’s programs and services in the ... primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... 19, 2017 , ... For the third year running, Noto ... the surrounding area, is inaugurating a charity event to help raise funds ... Lou Gehrig's disease or motor neurone disease, is a deadly neurological disorder that ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive year, ... Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, ... been chosen by their peers for the 2017 list based on their exceptional ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures ... **An FDAnews Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, ... Century Cures Act in order to thrive this year? , The passage of the ...
(Date:1/19/2017)... ... 19, 2017 , ... Each year, the Southeastern Society of ... hundreds of surgeons from over fifteen different countries come together to share and ... augmentation to breast reconstruction for breast cancer patients, teaching these surgical techniques ...
Breaking Medicine News(10 mins):